CLIA Kit for Gelsolin (GSN) Homo sapiens (Human) Sandwich CLIA

GS; AGEL; ADF; Brevin; Gelsolin Amyloidosis,Finnish Type; Actin-depolymerizing factor

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • CLIA Kit for Gelsolin (GSN) Packages (Simulation)
  • CLIA Kit for Gelsolin (GSN) Packages (Simulation)
  • CLIA Kit for Gelsolin (GSN) Results demonstration
  • SCA372Hu.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Gelsolin (GSN) and the recovery rates were calculated by comparing the measured value to the expected amount of Gelsolin (GSN) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 82-96 85
EDTA plasma(n=5) 84-92 89
heparin plasma(n=5) 84-102 93

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Gelsolin (GSN) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Gelsolin (GSN) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Gelsolin (GSN) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 90-104% 78-89% 78-99% 80-91%
EDTA plasma(n=5) 84-99% 98-105% 98-105% 97-104%
heparin plasma(n=5) 98-105% 84-98% 84-103% 82-98%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
Substrate A 1×10mL Substrate B 1×2mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;
8. Read RLU value immediately.

CLIA Kit for Gelsolin (GSN)

Test principle

The microplate provided in this kit has been pre-coated with an antibody specific to Gelsolin (GSN). Standards or samples are then added to the appropriate microplate wells with a biotin-conjugated antibody specific to Gelsolin (GSN). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is proportional to the Gelsolin (GSN) level in the sample or standard.;

Citations

  • Gelsolin in Cerebrospinal Fluid as a Potential Biomarker of EpilepsySpringerLink: 3585r8h46q7r0171
  • Treatment with gelsolin reduces brain inflammation and apoptotic signaling in mice following thermal injuryBioMed: 17422094
  • Application of iTRAQ quantitative proteomics in identification of serum biomarkers in breast cancerIEEE: 6098563
  • Investigation of the actin scavenging system in pre-eclampsiaPubmed: 24239294
  • Proteomic Study Reveals Plasma Protein Changes in Congenital Heart DiseasesPubmed: 24565402
  • The role of plasma gelsolin in cardiopulmonary bypass induced acute lung injury in infants and young children: a pilot studyPubmed:Pmc4132929
  • Gelsolin: Role of a Functional Protein in Mitigating Radiation InjuryPubmed:25164111
  • Plasma gelsolin and matrix metalloproteinase 3 as potential biomarkers for Alzheimer diseasePubMed: 25864780
  • Comparative mass spectrometric and immunoassay‐based proteome analysis in serum of Duchenne muscular dystrophy patientsPubmed:26680509
  • Comparative mass spectrometric and immunoassay-based proteome analysis in serum ofDuchenne muscular dystrophy patients.pubmed:26680509
  • Serum gelsolin levels in aneurismal subarachnoid hemorrhage: Preliminary results.pubmed:28365030
  • Urine-Based Biomarkers for Alzheimer's Disease Identified Through Coupling Computational and Experimental MethodsPubmed:30040720
  • Plasma gelsolin level predicts acute kidney injury after cardiopulmonary bypass in infants and young childrenPubmed:29427164
  • Production and Secretion of Gelsolin by Both Human Macrophage-and Fibroblast-like Synoviocytes and GSN Modulation in the Synovial Fluid of Patients with Various …Pubmed:35327525

Recommend products